Literature DB >> 19078681

Electrophysiologic assessment of shoulder girdle weakness in patients with cervical spondylosis: prognostic value of supraclavicular stimulation.

Toshikazu Tani1, Hiroki Kishimoto, Hideshi Tsuboya, Jun Kimura.   

Abstract

OBJECTIVES: We tested the use of supraclavicular stimulation as a prognostic measure of deltoid function after cervical spondylotic radiculopathy.
METHODS: Electrophysiological study consisted of supramaximally stimulating the brachial plexus and recording compound muscle action potentials (CMAPs) from the deltoid in 32 patients with unilateral weakness of 3 months or shorter duration as compared with 69 healthy subjects.
RESULTS: Despite considerable individual variability and age-related reduction in amplitude and area of deltoid CMAPs, the side-to-side ratios yielded useful, reproducible values. The measures recorded initially correlated significantly with the eventual recovery of deltoid strength but, interestingly, not with the initial degree of weakness. In particular, the CMAPs greater than 50%, even in the face of severe weakness, predicted a nearly complete return of function.
CONCLUSIONS: Supraclavicular stimulation provides a useful measure in monitoring deltoid weakness and predicting its recovery in patients with cervical spondylosis.

Entities:  

Year:  2002        PMID: 19078681     DOI: 10.1097/00131402-200209000-00003

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  2 in total

Review 1.  Cervical spondylotic amyotrophy.

Authors:  Sheng-Dan Jiang; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Eur Spine J       Date:  2010-08-08       Impact factor: 3.134

2.  Factors associated with an excellent outcome after conservative treatment for patients with proximal cervical spondylotic amyotrophy using electrophysiological, neurological and radiological findings.

Authors:  Yasuaki Imajo; Tsukasa Kanchiku; Hidenori Suzuki; Norihiro Nishida; Masahiro Funaba; Toshihiko Taguchi
Journal:  J Spinal Cord Med       Date:  2019-03-19       Impact factor: 1.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.